Engineering a novel protease-based Exendin-4 derivative for type 2 antidiabetic therapeutics.
Sign Up to like & getrecommendations! Published in 2018 at "European journal of medicinal chemistry"
DOI: 10.1016/j.ejmech.2018.03.050
Abstract: To develop an effective long-acting antidiabetic agent, we designed a novel Exendin-4 derivative (termed LEx4) containing an albumin-binding domain (ABD), a protease-cleavable linker and a native Exendin-4. Here, we present the LEx4 with balanced glucoregulatory… read more here.
Keywords: protease; native exendin; exendin derivative; engineering novel ... See more keywords